Detailed Molecular Mechanism and Potential Drugs for COL1A1 in Carboplatin-Resistant Ovarian Cancer

Detailed Molecular Mechanism and Potential Drugs for COL1A1 in Carboplatin-Resistant Ovarian Cancer

Carboplatin resistance in ovarian cancer (OV) is a major medical problem. Thus, there is an urgent need to find novel therapeutic targets to improve the prognosis of patients with carboplatin-resistant OV. Accumulating evidence indicates that the gene COL1A1 (collagen type I alpha 1 chain) has an im...

Full description

Bibliographic Details
Main Authors:	Feng Yang, Ziyu Zhao, Shaoyi Cai, Li Ling, Leying Hong, Liang Tao, Qin Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-02-01
Series:	Frontiers in Oncology
Subjects:	carboplatin ovarian cancer ceRNA KEGG drugs virtual screening
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2020.576565/full

Similar Items

Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?
by: Sevgi Ayhan, et al.
Published: (2023-09-01)

Dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin treatment for stage II-IV ovarian cancer patients
by: Zhenhua Du, et al.
Published: (2015-07-01)

Unilateral Optic Disc Papilloedema following Administration of Carboplatin Chemotherapy for Ovarian Carcinoma
by: Philippa Lewis, et al.
Published: (2014-01-01)

Investigation of Characteristics and Behavior of Loaded Carboplatin on the, Liposomes Nanoparticles, on the Lung and Ovarian Cancer: An In-Vitro Evaluation
by: Majid Hasanzadegan Roudsari, et al.
Published: (2016-04-01)

COM33 suppresses carboplatin-induced epithelial-mesenchymal transition via inhibition of Twist1 in ovarian cancer
by: Zhou Zhiyang, et al.
Published: (2022-12-01)

Limitations to the use of carboplatin-based therapy in advanced ovarian cancer
by: Christina Fotopoulou
Published: (2014-12-01)

Effective sequential combined therapy with carboplatin and a CDC7 inhibitor in ovarian cancer
by: Junping Li, et al.
Published: (2024-01-01)

Risk Factors of Hypersensitivity to Carboplatin in Patients with Gynecologic Malignancies
by: Yu-Hsiao Tai, et al.
Published: (2017-11-01)

Combined Interval Cytoreductive Surgery and Carboplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Advanced Primary High-Grade Serous Ovarian Cancer
by: Claudèle Brault, et al.
Published: (2023-12-01)

Expression profile of circular RNAs in continuous light-induced ovarian dysfunction
by: Yuling Li, et al.
Published: (2022-09-01)

The effect of consolidation treatment with intraperitoneal carboplatin in advanced epithelial ovarian cancers
by: Azamsadat Mousavi, et al.
Published: (2014-07-01)

LncRNA HOTAIRM1, miR-433-5p and PIK3CD function as a ceRNA network to exacerbate the development of PCOS
by: Hongmin Guo, et al.
Published: (2021-01-01)

The lnc-CTSLP8 upregulates CTSL1 as a competitive endogenous RNA and promotes ovarian cancer metastasis
by: Xinjing Wang, et al.
Published: (2021-05-01)

Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin
by: Shinichi Tate, et al.
Published: (2021-02-01)

Utilizing Patient-Derived Epithelial Ovarian Cancer Tumor Organoids to Predict Carboplatin Resistance
by: Justin W. Gorski, et al.
Published: (2021-08-01)

Expression characteristics of circular RNA in human traumatic brain injury
by: Zhenxing Li, et al.
Published: (2023-01-01)

Dose-dense regimen versus conventional three-weekly paclitaxel combination with carboplatin chemotherapy in first-line ovarian cancer treatment: a systematic review and meta-analysis
by: Wenjian Gong, et al.
Published: (2023-07-01)

Effect of CX3CL1/CX3CR1 gene polymorphisms on the clinical efficacy of carboplatin therapy in Han patients with ovarian cancer
by: Xin-Chen Wang, et al.
Published: (2023-01-01)

Select Per- and Polyfluoroalkyl Substances (PFAS) Induce Resistance to Carboplatin in Ovarian Cancer Cell Lines
by: Brittany P. Rickard, et al.
Published: (2022-05-01)

Differential age-related transcriptomic analysis of ovarian granulosa cells in Kazakh horses
by: Wanlu Ren, et al.
Published: (2024-01-01)

Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers
by: Adam Neal, et al.
Published: (2021-11-01)

Successful Chemotherapy with Carboplatin and S-1 for Thymic Carcinoma: A Case Report
by: Satoshi Igawa, et al.
Published: (2013-10-01)

Integrated analysis of lymphocyte infiltration-associated lncRNA for ovarian cancer via TCGA, GTEx and GEO datasets
by: Meijing Wu, et al.
Published: (2020-05-01)

A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics
by: Nicoletta Staropoli, et al.
Published: (2022-05-01)

Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel
by: Armstrong Stephen R, et al.
Published: (2012-11-01)

MiR-320b and miR-320d as Biomarkers to Predict and Participate in the Formation of Platinum Resistance in Ovarian Cancer Patients
by: Yuan-Yuan Liu, et al.
Published: (2022-05-01)

Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer
by: Huan Wang, et al.
Published: (2022-06-01)

The Comparison of Neutropenia and Peripheral Neuropathy Condition as an Impact of 3-hours and 24-hour Paclitaxel Infusion of Paclitaxel-Carboplatin Chemotherapy on Ovarian Cancer Patients
by: Primandono Perbowo, et al.
Published: (2019-07-01)

Hypersensitivity following Retreatment with Carboplatin a Decade after Completion of Primary Platinum-Based Chemotherapy
by: Laura Williams, et al.
Published: (2009-02-01)

Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy
by: Michelle W. Wong-Brown, et al.
Published: (2022-01-01)

A Whole Transcriptome Analysis in Peripheral Blood Suggests That Energy Metabolism and Inflammation Are Involved in Major Depressive Disorder
by: Yu Wang, et al.
Published: (2022-05-01)

CircRAD23B promotes proliferation and carboplatin resistance in ovarian cancer cell lines and organoids
by: Hui Wang, et al.
Published: (2024-01-01)

GATA1-induced upregulation of LINC01503 promotes carboplatin resistance in ovarian carcinoma by upregulating PD-L1 via sponging miR-766-5p
by: Yao Li, et al.
Published: (2021-08-01)

Major Clinical Impact of Platinum-Based Chemotherapy in a Patient with a Borderline Ovarian Cancer
by: Jian Chen, et al.
Published: (2009-09-01)

CircCSPP1 Functions as a ceRNA to Promote Colorectal Carcinoma Cell EMT and Liver Metastasis by Upregulating COL1A1
by: Qingyuan Wang, et al.
Published: (2020-06-01)

Activation of Adrenoceptor Alpha-2 (ADRA2A) Promotes Chemosensitization to Carboplatin in Ovarian Cancer Cell Lines
by: Haya Albanna, et al.
Published: (2023-11-01)

CircASH2L Promotes Ovarian Cancer Tumorigenesis, Angiogenesis, and Lymphangiogenesis by Regulating the miR-665/VEGFA Axis as a Competing Endogenous RNA
by: Jinxin Chen, et al.
Published: (2020-11-01)

Identification of Potential Prognostic Competing Triplets in High-Grade Serous Ovarian Cancer
by: Jian Zhao, et al.
Published: (2021-01-01)

Characterization of BRCA1/2-Directed ceRNA Network Identifies a Novel Three-lncRNA Signature to Predict Prognosis and Chemo-Response in Ovarian Cancer Patients With Wild-Type BRCA1/2
by: Meiling Zhang, et al.
Published: (2020-07-01)

Identification of competitive endogenous RNAs network in breast cancer
by: Xiaojin Wang, et al.
Published: (2019-05-01)